02:13 AM EDT, 08/24/2026 (MT Newswires) -- Roche (RO.SW) unit Genentech signed an exclusive licensing deal for HM17321, Hanmi Pharm's new treatment candidate for obesity and other chronic weight management and associated conditions. The license grants Genentech rights to develop, manufacture, and commercialize HM17321 worldwide, excluding South Korea, in exchange for an upfront payment of $190 million, according to a Monday release. The South Korean biopharmaceutical company could also receive additional payments related to development, regulatory, and commercial milestones, taking the total deal value to up to $2.3 billion. Genentech will assume responsibility for the development of HM17321 upon Hanmi's completion of the drug's ongoing phase 1 clinical trial.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.